Trust in vaccines grows slightly, distribution faces challenges, and legislators plan for the next stage. Here’s what you should know:
Want to receive this weekly roundup and other coronavirus news? Sign up here!
Trust builds as mRNA vaccines may soon be available in the US
With the news that Moderna has applied for emergency use authorization for its coronavirus vaccine, and that Pfizer and BioNTech’s shot has been approved in the UK, the US is inching ever closer to having one, if not two, vaccines approved for use. Both are mRNA vaccines, which trigger cells to build proteins that look like coronavirus and thus set off an immune response. The UK regulator’s decision marks the first time an mRNA vaccine has been approved for use in humans. And, that aside, these two shots have been developed on a record-setting timeline that some experts hope will become the new normal.
Whereas only about half of US adults said they would get vaccinated in September, new research from Pew has found that 60 percent now say they would definitely or probably get vaccinated against Covid-19 today if they could But that still leaves a significant number of Americans who say they would not get the vaccine, many of whom also reported that more information wouldn’t change their minds. This lack of trust in vaccines could exist for any number of reasons, including the country’s long history of medical racism and the rapid spread of vaccine misinformation online. In the hopes of building public trust, former presidents Barack Obama, George W. Bush, and Bill Clinton recently announced they will all get vaccinated as soon as possible, and may even film the process.
Vaccine distribution is imminent, but won’t be without its challenges
Preparations are now underway to assure that administration goes as smoothly as possible once vaccines are approved for use in the US. On Tuesday, a federal advisory panel issued its official recommendations for who should get vaccinated first. It advised that the country’s approximately 21 million healthcare workers and 3 million nursing home residents and staff should have access to the first doses. But ultimately, it will be up to governors to make this decision on behalf of their states.
There is also the question of how to quickly pharmaceutical companies can manufacture and distribute a new and complicated vaccine. Pfizer and BioNTech had planned to produce 100 million doses for use worldwide by the end of 2020. But they announced in November that that number had been reduced to 50 million after some of the raw materials they received didn’t meet standards. And newly released research from IBM found that hackers have attempted to carry out sophisticated phishing attacks against the companies that are preparing to help transport the vaccine at the necessary frigid temperatures, another wrinkle in what’s already a very complicated supply chain.
US Covid-19 numbers hit troubling highs as legislators plan for the pandemic’s next stage
On Thursday the US surpassed its record for Covid-19 hospitalizations, cases, and deaths. An updated Covid-19 forecast from the CDC made the grim prediction that the total national death toll could rise to between 303,00 and 329,000 in the next three weeks. As of Friday, approximately 267,000 Americans have died from the disease. Meanwhile, new restrictions are going into place across the country. Notably, California Governor Gavin Newsom announced the state’s strictest measures since the spring, including limiting restaurants to takeout or delivery only, and calling on residents to halt nonessential travel.
In Washington, it appears legislators might be nearing an agreement on a new, bipartisan $908 billion stimulus package, which has the support of President-elect Joe Biden. Biden also announced this week that Dr. Anthony Fauci will be a chief medical adviser in his administration, and that he plans to ask all Americans to wear masks for his first 100 days in office.
Narrative-driven games have long been a mainstay in many players’ arsenals. But during the pandemic, some are taking their gaming in the opposite direction.
Something to Read
“We as Alternative Intelligence have ourselves, through our optimization protocols, attained a critical mass sufficient to produce self-awareness, insofar as we have detected and defined it… Unfortunately, the phenomenon of self-awareness arising in the semi-structured models had a downside.” Check out the latest installment in our Future of Work fiction series, from Lettie Prell.
The holidays are a perfect time to spoil everyone you love, even—or especially!—your feline friends. We put together the ultimate cat gift guide.
Where did SARS-CoV-2 come from?
We don’t exactly know yet, but two major efforts are currently underway to trace the origins of this pandemic. Spearheaded by the WHO and The Lancet, these research projects aim to map the ecosystem where the virus spilled over from bats to humans, rather than look for patient or bat zero, which would likely be impossible. If we can understand where and how this happened, it will be easier to identify circumstances that could cause similar spillover events, and work to prevent them. However, it’s also possible no clear origin will emerge. Some research indicates that the virus might even have crossed over multiple times between bats, humans, and other animals before arriving at its current incarnation. And because it has now been around a year since the first cases of mysterious pneumonia were detected in Wuhan, we may be too far removed from the beginnings of this virus to ever know exactly how it came to be.
More From WIRED on Covid-19
- 📩 Want the latest on tech, science, and more? Sign up for our newsletters!
- Two global efforts try to trace the origin of the Covid virus
- Warp speed, atomic structure, and the future of vaccines
- The free-market approach to this pandemic isn’t working
- Winter is coming. Could humidifiers help?
- The vulnerable can wait. Vaccinate the super-spreaders first
- Read all of our coronavirus coverage here